A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
12/2006
12/27/2006	CN1883466A Preparation process of paclitaxel injection
12/27/2006	CN1883465A Apoferritin ¿Cplatinum anticancer drug composition and preparation method thereof
12/27/2006	CN1883455A A long-circulating nanoliposome carrier of hydroxycamptothecine and preparation method thereof
12/27/2006	CN1883454A Liposome administration system with tumor necrosis targeted antibody for preposition and application thereof
12/27/2006	CN1883453A An angiogenesis inhibitor and synergist thereof co-carried sustained-releasing anticancer medicinal injection
12/27/2006	CN1883452A An angiogenesis inhibitor and synergist thererof co-carried sustained-release anticancer agent
12/27/2006	CN1883451A A sustained-release anticancer injection containing angiogenesis inhibitor and synergist thereof
12/27/2006	CN1292073C Natural antitumor or antiviral substances and use of the same
12/27/2006	CN1292071C Attenuated vaccinia virus Tiantan strain vector and its preparation and application
12/27/2006	CN1292070C Recombinant eukaryon expression vector capable of simultaneously expressing two antisense bFGF and uses thereof
12/27/2006	CN1292002C Arginine deacylase fusion protein, method for preparation and application
12/27/2006	CN1292001C Nucleus factor-kB p50 subunit antagonist peptide, preparation and application thereof
12/27/2006	CN1292000C Nucleus factor-kB p65 subunit combination peptide, preparation and application thereof
12/27/2006	CN1291994C Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
12/27/2006	CN1291993C N-substituted benzothiazolyl-1-substituted phenyl-0,0-dialkyl-alpha-amino phosphonate ester derivatives, their preparation and application
12/27/2006	CN1291990C Biocidal compounds and their preparation
12/27/2006	CN1291988C Triazaspiro [5,5] undecane derivatrives and drugs containing the same as active ingredient
12/27/2006	CN1291984C 2-thio-substituted imidazole derivatives and use therof in pharmaceutical industry
12/27/2006	CN1291979C Imidazole compounds and their use as adenosine deaminase inhibitors
12/27/2006	CN1291755C Pharmaceutical compositions capable of enhancing the immunogenicity of poorly immunogenic antigens
12/27/2006	CN1291743C Traditional Chinese medicine for treating stomach cancer and its preparation technology
12/27/2006	CN1291742C Chinese herbal medicine for stomach carcinoma
12/27/2006	CN1291713C Novel composition with taxane as major component
12/26/2006	US7153997 N-hydroxyphenoxyphenyl derivatives of glycine or valine, e.g., N-[3,5-Dichloro-4-(4-hydroxy-3-isopropyl-5-methylphenoxy)benzoyl]glycine; treating metabolic disorders or diseases dependent upon the expression of a T3 regulated gene
12/26/2006	US7153964 Pyrimidine compounds
12/26/2006	US7153963 Phenylalanine derivatives
12/26/2006	US7153958 Farnesyl transferase inhibiting benzoheterocyclic derivatives
12/26/2006	US7153951 A biologically active peptide at least 85% identical to a peptide: (a) X01ValSerGluX02GlnLeuX03HisX04X05GlyLysX06; (b) fragments containing amino acids 1-9, 1-10, 1-11, 1-12,(c) a salt or (d) N- or C- derivatives
12/26/2006	US7153946 Molecular conjugates for use in treatment of cancer
12/26/2006	US7153940 C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
12/26/2006	US7153936 A peptide of at least 5 amino acids containing a unique portion of a semaphorin, and such peptide has a semaphorin binding specificity
12/26/2006	US7153932 Immunotoxins comprising ribosome-inactivating proteins
12/26/2006	US7153887 Treatment anti-neutrophil cytoplasmic antibodies-associated vasculitis in a patient resistant to corticosteroid treatment by administering gusperimus or its salt in cycles
12/26/2006	US7153885 Stolonoxides
12/26/2006	US7153884 C-2′ methylated derivatives of paclitaxel for use as antitumour agents
12/26/2006	US7153879 E.g., 7,11-Di(hydroxy)-8,8,10,12,16-pentamethyl-3-(1-methyl-2-(methylthiazol-4-yl)ethenyl)-4-aza-17-oxabicyclo(14.1.0)heptadecane-5,9-dione, preferably Form A; anticarcinogenic, -proliferative, -diabetic, -inflammatory agents; viricides; autoimmune diseases; psoriasis; agents; cardiovascular disorders
12/26/2006	US7153875 Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
12/26/2006	US7153872 Cancer and fibrotic diseases
12/26/2006	US7153862 αv integrin receptor antagonists
12/26/2006	US7153857 antiinflammatory agents; antiarthritic agents; anticancer agents
12/26/2006	US7153856 Orally administering N-(2-chloro-6-methylphenyl)-2-[4-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-6-ylamino]thiazole-5-carboxamide for treating cancer
12/26/2006	US7153853 Heterocyclic compounds and antitumor drugs containing the same as the active ingredient
12/26/2006	US7153846 2-(3,4,5-trihydroxy-2-methoxy-8-methyl-6-decenoylamino)-E-caprolactams that may be esterified; treatment of cancer, especially cancers of the breast, colon, lung, and prostate and glioblastomas and leukemia
12/26/2006	US7153844 Estrogen-linked platinum (II) complexes as anticancer agents
12/26/2006	US7153841 Conjugates with carriers; red shifted absorption; antiproliferative and antitumor agents; benign prostatic hyperplasia; diagnosis
12/26/2006	US7153833 Therapeutic uses of SMR1 peptides
12/26/2006	US7153825 Administering an exendin modified with a polyethylene glycol, gelatin and/or albumin to increase its biological half-life; treating hyperglucagonemia and diabetes, especially type II diabetes
12/26/2006	US7153678 Polynucleotides encoding the novel human phosphatase, RET31, and variants thereof
12/26/2006	US7153669 Nucleotide sequences coding protein for use in the diagnosis, treatment and prevention of autoimmune, cell proliferative and inflammatory diseases
12/26/2006	US7153507 A human monoclonal antibody specifically binds to human IL-15 and to inhibit IL-15-induced proinflammatory effects; tumor necrosis factor; antiinflammatory, -arthritic, -carcinogenic, proliferative agents; rheumatic diseases; transplants
12/26/2006	US7153506 Treating cancer whereof the cells exhibit overexpression of a product of a gene of the myc-related family
12/26/2006	US7153499 Promoting differentiation and maturation of immature dendritic cells in a regional lymph node (especially by administering a natural cytokine mixture parilymphatically) so that the cells deliver T-cell antigen to effect immunization
12/26/2006	US7153490 Liposomes encapsulating anticancer drugs and use thereof in the treatment of malignant tumors
12/21/2006	WO2006135796A2 Crystalline forms of a pyrrolotriazine compound
12/21/2006	WO2006135762A1 Identification of a folliculin-binding protein fnip1
12/21/2006	WO2006135721A1 Alkylquinoline and alkylquinazoline kinase modulators
12/21/2006	WO2006135719A1 Aminopyrimidines as kinase modulators
12/21/2006	WO2006135718A1 Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
12/21/2006	WO2006135644A1 Aminopyrimidines as kinase modulators
12/21/2006	WO2006135636A2 Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators
12/21/2006	WO2006135630A1 Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
12/21/2006	WO2006135629A1 Synergistic modulation of flt3 kinase using alkylquinolines and alkylquinazolines
12/21/2006	WO2006135109A1 Method for treatment of proliferative disease utilizing inhibition of formation of synoviolin homooligomer
12/21/2006	WO2006134989A1 Nitrogenated heterocyclic compound
12/21/2006	WO2006134877A1 Injection
12/21/2006	WO2006134489A1 Sulindac derivatives for treatment of cancer
12/21/2006	WO2006134318A1 Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
12/21/2006	WO2006133885A1 Tricyclic fused indole derivatives and their use as aurora kinase inhibitors
12/21/2006	WO2006133821A1 Tetrahydroquinolines used in the form of modulators of mitotic motor-proteins eg5
12/21/2006	WO2006133805A1 Tetrahydroquinoline derivatives
12/21/2006	WO2006133708A1 Bioactive agents produced by submerged cultivation of a basidiomycete cell
12/21/2006	WO2006133654A1 USE OF NF-κB INHIBITOR FOR TREATING SEVERAL DISEASES
12/21/2006	WO2006133634A1 Tetrahydroindole derivatives and tetrahydroindazole derivatives, and use thereof
12/21/2006	WO2006133611A1 N2-quinolyl or isoquinolyl substituted purine derivatives, the preparation and uses thereof
12/21/2006	WO2006133561A1 Method of cancer treatment using sirna silencing
12/21/2006	WO2006133510A1 Liquid pharmaceutical formulations of docetaxel
12/21/2006	WO2006133498A1 Acid addition salts of n-ethyi-n'-[2-methoxy-4-(5-methyi-4-{[(1s)-1-pyridin-3-ylbutyi]amino}pyrimidin- 2-yl)phenyl]urea and uses thereof
12/21/2006	WO2006106311A3 Combination treatment methods for treating sex-hormone dependent disease and fertility treatment
12/21/2006	WO2006099015A3 Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders
12/21/2006	WO2006096461A3 Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent
12/21/2006	WO2006059063A3 Perfluorocarbon liquids as carcinogen
12/21/2006	WO2006056888A3 Glycine as a diet supplement for the treatment of health problems that result from underlying metabolic disorders
12/21/2006	WO2006014999A3 Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease
12/21/2006	WO2005121172A8 Peptide capable of altering tubulin polymerization and use thereof for inhibiting cell proliferation
12/21/2006	WO2005110994A8 Substituted pyrazolyl urea derivatives useful in the treatment of cancer
12/21/2006	WO2005100399A3 Dr5 antibodies and uses thereof
12/21/2006	US20060288434 Inhibiting angiogenesis in a mammal by administering an antibody which specifically binds to EphriniB2 or EphB4; cardiovascular disorders
12/21/2006	US20060287536 Phenyl-thiophene type vitamin d receptor modulators
12/21/2006	US20060287513 Compositions and methods for the therapy and diagnosis of breast cancer
12/21/2006	US20060287396 4-aryl quinols and analogs thereof as therapeutic agents
12/21/2006	US20060287371 E.g., pentamethyl-16-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-1-aza-13(Z)-cyclohexadecene-2,6-dione and 4S-[4R,7S,8R,9R,15R*(E)]]-4,8-dihydroxy-5,5,7,9,13,16-hexamethyl-16-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-1-oxa-13-cyclohexadecene-2,6-dione; antiproliferative agents
12/21/2006	US20060287340 e.g. 5-(4-fluorophenyl)-N-[2-(1-methyl-2-oxo-1,7-diazaspiro[4,4]nonan-7-yl)-6-quinolinyl]-2-pyrimidinecarboxamide; melanin concentrating hormone receptor antagonist; central nervous system disorders, cardiovascular disorders and metabolic disorders
12/21/2006	US20060287339 Aza- and polyazanthranyl amides and their use as medicaments
12/21/2006	US20060287338 Metalloproteinase inhibitor compounds
12/21/2006	US20060287320 Preparation of thioarabinofuranosyl compounds and use thereof
12/21/2006	US20060287295 Antiproliferative agent in the prevention or treatment of tumors which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases;1-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}methyl)-L-prolinamide
12/21/2006	US20060287281 Phosphohalohydrins, process for the production thereof and use thereof
12/21/2006	US20060287274 Phosphoepoxides, method for making same and uses
12/21/2006	US20060287268 Splice-region antisense composition and method
12/21/2006	US20060287241 Combination comprising N-(3-methoxy-5-methylpyrazin-2yl)-2-(4-[1,3,4-oxadiazol-2-y1]pyridine-3-sulphonamide and an lhrh analogue and/or bisphosphonate

1 ... 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 ... 2211